R
Richard E. Champlin
Researcher at University of Texas MD Anderson Cancer Center
Publications - 1500
Citations - 73470
Richard E. Champlin is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Transplantation & Hematopoietic stem cell transplantation. The author has an hindex of 138, co-authored 1402 publications receiving 66917 citations.
Papers
More filters
Journal ArticleDOI
Delay of alternative antiviral therapy and poor outcomes of acyclovir-resistant herpes simplex virus infections in recipients of allogeneic stem cell transplant - a retrospective study.
Ella J. Ariza-Heredia,Roy F. Chemaly,Lokesh R Shahani,Ying Jang,Richard E. Champlin,Victor E. Mulanovich +5 more
TL;DR: In conclusion, acyclovir‐resistant HSV infection is more likely during the period of profound deficit in T‐cell‐mediated immunity and is associated with significant morbidities.
Journal ArticleDOI
Stem cell transplantation for chronic lymphocytic leukemia: should not more patients get a transplant?
TL;DR: Novel therapeutic approaches with conventional chemotherapy and monoclonal antibody combinations have improved the complete remission rates in chronic lymphocytic leukemia, but cure remains elusive, particularly in fludarabine-refractory patients, whose prognosis remains poor.
Journal ArticleDOI
A Randomized Phase II Trial of Fludarabine/Melphalan 100 versus Fludarabine/Melphalan 140 followed by Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Multiple Myeloma
Qaiser Bashir,Hassan Khan,Peter F. Thall,Ping Liu,Nina Shah,Partow Kebriaei,Simrit Parmar,Betul Oran,Stefan O. Ciurea,Yago Nieto,Roy B. Jones,Chitra Hosing,Uday R. Popat,Yvonne T Dinh,Gabriela Rondon,Robert Z. Orlowski,Jatin J. Shah,Marcos de Lima,Elizabeth J. Shpall,Richard E. Champlin,Sergio Giralt,Muzaffar H. Qazilbash +21 more
TL;DR: On multivariate analysis, disease status at allo-HCT, complete response or very good partial response (VGPR) was significantly associated with longer PFS (15.6 versus 9.6 months in patients with newly diagnosed, relapsed, or primary refractory myeloma).
Journal Article
High-dose melphalan allows durable engraftment of allogeneic bone marrow
TL;DR: Four patients who had prompt engraftment after conditioning with melphalan-based chemotherapy regimens (BEAM or busulfan/melphalan) are reported, indicating that theseMelphalan regimens are sufficiently immunosuppressive to allow sustained engraftments and donor hematopoiesis.
Journal ArticleDOI
Intravenous BU plus Mel: An effective, chemotherapy-only transplant conditioning regimen in patients with ALL
Partow Kebriaei,Timothy Madden,X. Wang,Peter F. Thall,Celina Ledesma,M. de Lima,Elizabeth J. Shpall,Chitra Hosing,Muzaffar H. Qazilbash,Uday R. Popat,Amin M. Alousi,Yago Nieto,Richard E. Champlin,Roy B. Jones,Borje S. Andersson +14 more
TL;DR: The administration of i.v. BU combined with melphalan (Mel) in patients with ALL undergoing allogeneic hematopoietic SCT and the 2-year OS, PFS and non-relapse mortality (NRM) rates were favorable and significantly higher for patients older than 40 years, mainly due to GVHD.